APA (7th ed.) Citation

Holman, C. M. (2025). Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc: United States Court of Appeals of the Federal Circuit, 2025 130 F.4th 1363. Biotechnology Law Report, 44(3), 200. https://doi.org/10.1089/blr.2025.80803.mer

Chicago Style (17th ed.) Citation

Holman, Christopher M. "Merck Sharp & Dohme B.V. V. Aurobindo Pharma USA, Inc: United States Court of Appeals of the Federal Circuit, 2025 130 F.4th 1363." Biotechnology Law Report 44, no. 3 (2025): 200. https://doi.org/10.1089/blr.2025.80803.mer.

MLA (9th ed.) Citation

Holman, Christopher M. "Merck Sharp & Dohme B.V. V. Aurobindo Pharma USA, Inc: United States Court of Appeals of the Federal Circuit, 2025 130 F.4th 1363." Biotechnology Law Report, vol. 44, no. 3, 2025, p. 200, https://doi.org/10.1089/blr.2025.80803.mer.